...
首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
【24h】

Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety

机译:具有末端磺酰胺部分的新型1,3,4-三芳基吡唑衍生物的设计,合成,体外抗癌评估,激酶抑制作用和药代动力学谱

获取原文

摘要

The present work describes the design and synthesis of a novel series of 1,3-diaryl-4-sulfonamidoarylpyrazole derivatives 1a-q and 2a-q and their in vitro biological activities. The target compounds were evaluated for antiproliferative activity against NCI-60 cell line panel. Compounds 1c, 1g, 1k-m, 1o, 2g, 2h, 2k-m, 2o, and 2q showed the highest mean inhibition percentages at 10?μM single-dose testing and were selected to be tested at 5-dose mode. The ICs50 of the most potent compounds were determined over the 60 cell lines. Compound 2l exhibited the strongest activity against different cell lines with IC50 0.33?μM against A498 renal cancer cell line. Compound 2l was tested over a panel of 20 kinases to determine its molecular target(s), and its IC50 values over the most sensitive kinases were defined. In vitro stability and in vivo pharmacokinetic profile of compound 2l was also investigated.
机译:本工作描述了一系列新型的1,3-二芳基-4-磺酰胺基芳基吡唑衍生物1a-q和2a-q的设计和合成及其体外生物学活性。评价目标化合物对NCI-60细胞系的抗增殖活性。化合物1c,1g,1k-m,1o,2g,2h,2k-m,2o和2q在10?μM单剂量试验中显示出最高的平均抑制百分数,并选择以5剂量模式进行试验。在60个细胞系中测定了最有效的化合物的IC50。化合物2l针对不同细胞系表现出最强的活性,针对A498肾癌细胞的IC50为0.33?μM。在一组20种激酶中测试了化合物21,以确定其分子靶标,并定义了其对最敏感激酶的IC50值。还研究了化合物2l的体外稳定性和体内药代动力学特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号